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In order to infuse hemoglobin into the vasculature as an oxygen therapeutic or blood substitute, it is
necessary to increase the size of the molecule to enhance vascular retention. This aim can be achieved
by PEGylation. However, using non-specific conjugation methods creates heterogenous mixtures and
alters protein function. Site-specific PEGylation at the naturally reactive thiol on human hemoglobin
(βCys93) alters hemoglobin oxygen binding affinity and increases its autooxidation rate. In order to avoid
this issue, new reactive thiol residues were therefore engineered at sites distant to the heme group and
the α/β dimer/dimer interface. The two mutants were βCys93Ala/αAla19Cys and βCys93Ala/βAla13Cys. Gel
electrophoresis, size exclusion chromatography and mass spectrometry revealed efficient PEGylation at
both αAla19Cys and βAla13Cys, with over 80% of the thiols PEGylated in the case of αAla19Cys. For both
mutants there was no significant effect on the oxygen affinity or the cooperativity of oxygen binding.
PEGylation at αAla19Cys had the additional benefit of decreasing the rates of autoxidation and heme
release, properties that have been considered contributory factors to the adverse clinical side effects
exhibited by previous hemoglobin based oxygen carriers. PEGylation at αAla19Cys may therefore be a
useful component of future clinical products.
Introduction
Infusing extracellular hemoglobin (Hb) into the vasculature
has clinical potential as a blood substitute,1 oxygen carrying
therapeutic2 or drug delivery agent.3 However, native hemo-
globin is in rapid equilibrium between tetrameric (≈64 kDa)
and dimeric (≈32 kDa) forms. The dimer is rapidly cleared via
the kidneys, both damaging renal function4 and significantly
decreasing the plasma lifetime of extracellular Hb.5 Therefore,
either chemical or genetic modifications have been used to
prevent renal clearance and enhance plasma lifetime.6 The
resultant Hemoglobin Based Oxygen Carrier (HBOC) is able to
function to transport oxygen in the circulation for several days
following infusion.
One modification is to mimic the protective effects of the
red blood cell via encapsulating Hb into natural or artificial
vesicles.7 Alternatively covalent cross-linking of subunits –
either using chemical5 or genetic8 means – can increase the
minimum molecular size of Hb preventing renal clearance. If
the cross-linked protein is large enough it can also decrease
unwanted extravasation of the protein into the surrounding
tissue, potentially preventing the undesirable scavenging of
the intercellular messenger nitric oxide.9 An attractive alterna-
tive to these methods is conjugation with large unreactive
organic molecules such as poly(ethylene glycol) (PEG). PEG is
particularly attractive as it has been shown to decrease immu-
nogenicity and extend the circulatory lifespan of modified pro-
teins10 and is used in many licensed pharmaceutical pro-
ducts.11 PEGylation of human Hb was used in previous HBOC
products in clinical trials by Sangart (MP4, Hemospan12),
APEX Pharmaceuticals (PHP13) and Baxter Healthcare
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(rHb2.0 14). PEGylation of bovine Hb is used in Sanguinate®,15
a current product being trialed by Prolong Pharmaceuticals.
Activated PEGs are able to conjugate to proteins as acylating
reagents, alkylating reagents, or thiol-reactive reagents.11
Human Hb has only one reactive sulfhydryl residue per dimer
that can be readily PEGylated using standard thiol reactive
agents such as maleimide-PEG (MAL-PEG). Modifications at
this site (βCys93) increase – albeit only slightly – the oxygen
affinity of Hb.16 However, of greater concern they increase the
autoxidation rate of oxyhemoglobin (oxyHb) and make Hb
more liable to oxidative damage17 and heme loss.18
Modifications at this site (nitrosation, glutathionylation)
in vivo have also been suggested to play an important role in a
signaling function of Hb that may be important to maintain in
a HBOC.19 Reactivity at βCys93 can be maintained in
PEGylated Hb by protecting this residue prior to modification
at other surface residues.20
Maleimide-PEG conjugation at non cysteine residues is
possible via the use of reagents such as 2-iminothiolane to
introduce thiol reactivity at terminal amino residues and
surface lysines. Such methods of PEGylation have been used
successfully in the design of HBOC products tested in animal
models (and clinical trials) such as Hemospan,21 Euro-
PEG-Hb22 and Sanguinate®.23 However, two issues have
arisen. The first is that the final product is very heterogeneous,
due to differences in the efficiency at different protein sites of
the reactions both creating free thiol residues and/or the sub-
sequent PEGylation at those residues. Heterogenous products
also arise when bifunctional activated PEG reagents react at
primary amines in Hb as is the case with PHP. HBOCs formed
in these ways can have as few as 0 or as many as 14 PEG chains
bound.24,25 A heterogeneous product makes it difficult to test
and control the reactivity and side reactions of Hb fractions
that may be only small components of the product, but could
lead to altered reactions in vivo. In this context, it is perhaps
noteworthy that preclinical and clinical data led to Biopure
modifying their heterogenous cross-linked HBOC products
(HS1, HS-2) to create more homogenous products for veterin-
ary (Oxyglobin®) and clinical use (Hemopure®).26
The second problem is that non-specific PEGylation fre-
quently includes residues key to dimer–dimer interactions at
the α/β interface. Therefore, these products are frequently
dimeric. Although the PEGylated dimers are still too large for
rapid renal filtration, they take on some of the properties of
the Hb dimer (enhanced autoxidation, high oxygen affinity, no
cooperativity). Although this high affinity was marketed as a
useful feature in Hemospan,12 this does restrict the ability to
modify Hb functions in any new product. PEGylation under
controlled conditions in the absence of oxygen favors the T
state of Hb, increasing the concentration of tetrameric
HBOC,27 but does not completely remove the problem.24
For these reasons it would be useful to generate a HBOC
that is derived from homogenous PEGylation at a site that
does not perturb the functional properties of Hb. A recombi-
nant Hb carrying a single reactive free surface cysteine at a site
remote from the dimer/tetramer interface could possess these
desirable qualities. Therefore, this paper tests the efficacy and
functional effects of homogenous PEGylation in human Hb at
βCys93 (wild type) and two new positions generated by repla-
cing existing alanine residues with cysteine; βAla13Cys is a site
homologous to a surface cysteine naturally occurring in feline
Hb and αAla19C is a completely novel site on the α subunit.
Results
Fig. 1 shows the sites chosen for mutation to introduce exter-
nal, reactive cysteine residues suitable for PEGylation at sites
remote from the dimer/tetramer interface. PMB reacts with
exposed sulfhydryl residues yielding an absorbance change in
the UV. For a single exposed residue in the α (as in A12) or β
subunit (as in A1 and A13), the reaction would be expected to
be complete at a 0.5 : 1 PMB : Hb ratio (measuring [Hb] on a
per heme basis). PMB reactivity (Fig. 2) was therefore consist-
ent with the lack of any exposed residues in A11 and the pres-
ence of two exposed residues per Hb tetramer in A1, A12 and
A13 i.e one per α or β subunit.
HbCO (R state Hb) was tested to limit undesirable oxidative
reactivity during any subsequent PEGylation and purification
process. Consistent with previous findings14 there were two
reactive thiol residues per α2β2 tetramer for wild type Hb (A1)
at βCys93. No reaction was observed when βCys93 was con-
verted to alanine (A11). The creation of new sulfhydryl sites in
the α-subunit (A12: βCys93Ala/αAla19Cys) or the β-subunit
(A13: βCys93Ala/βAla13Cys) restored this reactivity.
It is important that any new Hb mutations introduced into
a putative HBOC do not increase the oxidation of Hb, nor
facilitate the release of the heme cofactor. Fig. 3 shows the
stability of the recombinant proteins towards autoxidation and
heme loss. A12 has lower autoxidation than native Hb. A11
and A12 have lower heme loss than native Hb, whereas
A13 has greater heme loss than native Hb. However, in all
cases the reactivity is only slightly different to native Hb, indi-
cating that any post translational modifications (or lack of
Fig. 1 Stereo view of mutation sites for PEGylation. An αAla19Cys and
βAla13Cys mutation introduced reactive thiol sites for PEGylation for A12
(red) and A13 (yellow) respectively. For both A12 and A13 the βCys93 site
was mutated to an Alanine residue (green). α-Subunit is in purple,
β-subunit in blue and heme as white stick. PDB was 1A3N, human
hemoglobin (deoxy) mutations were in silico.
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such modifications) in the recombinantly produced proteins
exert rather small effects on reactivity in the heme pocket.
SDS-PAGE (Fig. 4) shows the dominant fraction of the
recombinant Hb is consistent with α and β monomers
(16 kDa). Consistent with the presence of a free sulfhydryl
residue, A1, A12 and A13 are all able to react with 20 kDa
MAL-PEG. As seen previously for many proteins,28,29 including
Hb,21,24 PEGylated protein adducts run at a slightly higher
apparent molecular weight than predicted from unPEGylated
protein molecular weight markers. This discrepancy between
apparent and real molecular weights in SDS-PAGE of
PEGylated Hb can be shown by excising the band and using
mass spectrometry.24 Under the conditions of Fig. 4, barium
iodide staining showed that the unreacted PEG ran at twice the
apparent molecular weight compared to a protein of similar
size. So in the case of the Hb monomer (16 kDa) we would
expect to observe a mono-20 kDa PEGylated Hb band at ca.
56 kDa (16 kDa for the protein portion plus an apparent
40 kDa for the PEG). The gels in Fig. 4 are therefore consistent
with the major new product being Hb (16 kDa) bound to a
single (20 kDa) PEG. Note in all cases one subunit will be
unreactive to MAL-PEG so that a band remains at 16 kDa – the
α-subunit in A1 and A13 and the β-subunit in A12. The visual
inspection and the densitometric analysis of gels indicate that
A11, A12 and A13 preparations contain a small band at around
30–35 kDa, consistent with an unPEGylated covalent dimer. In
some samples of A12 and A13 the proportion of the band in
this region increased significantly. In these cases, the excess
could be decreased by treatment with dithiothreitol (DTT).
However, even post DTT treatment a band remained,
suggesting the possibility of a fraction of covalently bound
dimer other than a disulfide bridge.
LC-MS QTOF analysis revealed molecular mass for the
dominant Hb species both pre and post-DTT treatment of
15289 and 15966, consistent with α and β-subunits with
uncleaved N-terminal methionine residues, as is usual for
recombinant Hb (see Fig. S1† for A12 data). A minor species
observed was more heterogenous, with dominant masses of
30578 and 31932, consistent with the presence of αα and ββ
dimers.
Sulfhydryl reactivity and PEGylation of Hb has previously
been shown to be partially dependent on the conformational
state of the protein (R state or T state). The natural βCys93 site
(A1) is more exposed in the R state (favored in oxyHb).30 If a
new reactive cysteine was introduced on the surface, distant
Fig. 2 PMB reactivity of Hb mutants. Absorbance change as a function
of increasing PMB. Conditions as per materials and methods. Legend:
A1, open triangles; A11, filled squares; A12 filled triangles; A13, open
circles.
Fig. 3 Autoxidation and heme loss. For assay conditions see Materials
and methods. Mean ± SD. Statistical significance (using the Student’s
t-test comparing each recombinant Hb to native human Hb (A0): *p <
0.05, **p < 0.01, ***p < 0.001.
Fig. 4 SDS-PAGE before and after PEGylation. For conditions see
Materials and methods.
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from parts of the protein that undergo large conformational
changes, this differential effect might be absent. This was con-
firmed in Fig. 5, which shows MAL-PEG reactivity to mutants
in R-state Hb (CO-bound) or T-state (deoxygenated). Under the
latter conditions, before PEGylation, when hemoglobins were
deoxygenated, ascorbate (0.2 mM) was also added as a redu-
cing agent during the reaction. Under both conditions A12
and A13 showed more efficient conjugation than A1 with
approximately 50% of the Hb subunits binding PEG (as
expected for reactivity at the single external residue in the α-
(A12) or β-subunit (A1, A13). Again, no reactivity was seen in
the mutant only lacking βCys93 (A11).
It is desirable for PEGylation to be efficient and result in a
homogenous HBOC. The extent of PEGylation and the hetero-
geneity of PEGylated Hb derivatives were evaluated via size
exclusion chromatography (SEC) (Fig. 6 and S2†), under con-
ditions where Hb is predominantly dimeric. Results show that
PEGylated A12 is more homogenous than PEGylated A13.
Moreover, A1 shows a significant amount of unPEGylated
protein. The SEC analysis also revealed the presence of a frac-
tion of tetramers for both A12 and A13. This is possibly associ-
ated with the reaction of the exposed cysteines and formation
of a disulfide bridge between two dimers. However, this did
not seem to unduly retard PEGylation efficiency which reveals
the order A12 > A13≫ A1.
The molecular mass of the MAL-PEG adducts was deter-
mined using MALDI/TOF spectrometry (Fig. 7), under oxyge-
nated CO-saturated (oxy) and anaerobic (deoxy) conditions
for A12 (Fig. 7A) and A13 (Fig. 7B). In the region
14 000–17 000 m/z, A12 and A13 showed both α and β peaks,
while in the region 30 000–34 000 three peaks, corresponding
to α–α, α–β, and β–β complexes appeared. This is possibly
due to artifacts generated by the denaturing conditions used
for the mass spectrometry and was also observed for
samples of native human HbA0. Upon PEGylation in both R
and T state conditions, the A12 sample (Fig. 7A) shows an
almost complete disappearance of the peak corresponding to
the α chain, in agreement with derivatization of the intro-
duced α Cys19 with 20 kDa MAL-PEG that now exhibits a
broad peak around 36 000 m/z. Similarly, for A13 (Fig. 7B),
there is an almost complete disappearance of the peak
corresponding to the β chain, in agreement with derivatiza-
tion of the introduced β Cys13 with 20 kDa MAL-PEG that
exhibits a broad peak around 36 000 m/z. It is known that
PEG-conjugated proteins exhibit a low propensity to fly and,
consequently, they give low signals in mass spectrometers.
However, it is clear that the dominant protein product for
A12 corresponds to a β-subunit and an α-subunit with a
single PEG bound. Likewise, A13 predominantly comprises
an α-subunit and a β-subunit with a single PEG bound.
Fig. 5 PEGylation efficiency in R-state and T-state Hb. SDS-PAGE of
PEGylated Hb A1, A11, A12 and A13 in CO-saturated (left) and anaerobic
(right) conditions. Unstained Precision Plus Protein® standards (Biorad)
were used as MW markers (25, 50 and 75 kDa bands are highlighted in
the gel). For assay conditions see Materials and methods.
Fig. 6 Size exclusion chromatography pre and post PEGylation. SEC of Hb mutants pre (left panel) and post (right panel) PEGylation. For conditions
see Materials and methods. For an example of protein MW standards run at the same time as A12 Hb see Fig. S2.† Comparison with SEC standards
reveals Hb mutant peaks at 10.8–10.9 min comprise Hb dimer and peaks at 9.9 min tetramer. Hb PEG peaks at 7.7–7.8 min comprise PEGylated
dimers. The minor peak at 6.7–6.8 is not straightforward to assign without further analysis. It could be a PEGylated tetramer, but it might also be a
different high MW species, e.g. nonspecific protein aggregates or possibly di-PEGylated Hb.
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The kinetics of MAL-PEG reactivity was explored in A12 by
varying the concentration and time of incubation (Fig. 8). As
there are two reactive thiols per tetramer, 100% efficiency with
no side reactions or unreacted Hb would have led to 50 : 50
end ratios of Hb monomer to Hb–PEG adduct. Increasing the
PEG : Hb ratio during incubation (from 3 : 1 from 12 : 1) and
the length of the incubation (from 1–3 h) increased the
efficiency of PEGylation in A12. However, the increase was
rather small – judged on a per α-subunit basis – from 66% at
the lowest PEG ratio (3 : 1) and shortest incubation time (1 h)
to 82% at the highest PEG ratio (12 : 1) and longest incubation
time (3 h).
Cooperative oxygen binding is likely to be a useful function
in a HBOC and in our mutants, unusually for PEGylated Hb,
cooperative oxygen binding was maintained. A12 and A13
PEGylation had no significant effect on oxygen affinity or the
Hill coefficient for cooperative binding, although A1 – consist-
ent with previous findings17 – showed a small, but significant,
increase in affinity (Table 1 and Fig. S3†).
As A12 showed the most efficient PEGylation of our
mutants, it was characterized in more detail. PEGylation of
A12 resulted in a more stable protein with a decrease in autoxi-
dation and heme loss compared to A1 or unPEGylated A12
(Table 2, Fig. S4 and S5†). Antioxidant reductants such as
Table 1 Effect of PEGylation on oxygen binding to heme
P50
(torr)
P50 (torr)
(after PEG)
Hill
coefficient
Hill coefficient
(after PEG)
A1 WildType (β-C93) 5.0 ± 0.3 3.8 ± 0.2* 1.7 ± 0.2 1.9 ± 0.2
A13 β-A13C/β-C93A 4.2 ± 0.2 4.6 ± 0.2 1.9 ± 0.3 2.0 ± 0.2
A12 α-A19C/β-C93A 4.4 ± 0.2 4.1 ± 0.2 1.6 ± 0.2 1.6 ± 0.1
P50 measured in mmHg. *p < 0.05 compared to pre-PEGylated value.
Fig. 7 MALDI-TOF of A12 PEG and A13 PEG. Arrows indicate expected
positions of α-subunit and β-subunit pre and post PEGylation by a single
20 kDa PEG. Peaks in the 31 000–32 000 m/z region indicate presence
of unPEGylated dimers.
Fig. 8 Effect of conditions on PEGylation efficiency. SDS-PAGE con-
ditions as in Materials and methods. Lanes indicate different lengths of
treatments at different PEG : Hb ratios. Bands were quantified by densi-
tometry and the relative % of total protein stained indicated for each
band.
Table 2 Effect of PEGylation on stability and reducibility of Hb
A1 WildType (β-C93) A12 α-A19C/β-C93A A12-PEG
Autoxidation 0.052 ± 0.020 min−1 0.048 ± 0.010 min−1 0.029 ± 0.003 min−1 *
Heme release 0.046 ± 0.001 min−1 0.040 ± 0.010 min−1 0.035 ± 0.007 min−1 *
Ferryl reduction by ascorbate
High affinity rate (α subunit) Vmax 0.026 ± 0.003 s−1 Vmax 0.024 ± 0.001 s−1 Vmax 0.014 ± 0.002 s−1 *
KM 14.6 ± 5.9 µM KM 4.32 ± 1.15 µM KM 18.25 ± 7.87 µM *
Autoreduction rate (α subunit) 0.0066 s−1 0.0040 s−1 0.0057 s−1
Low affinity rate (β subunit) Vmax 0.015 ± 0.001 s−1 Vmax 0.0074 ± 0.0007 s−1 Vmax 0.015 ± 0.001 s−1 *
KM = 205.7 ± 40.1 µM KM = 47.1 ± 19.0 µM KM = 417.2 ± 295.1 µM *
Autoreduction rate (β subunit) 0.0013 s−1 0.0008 s−1 0.0009 s−1
*p < 0.05 compared to A12 pre-PEGylated value (determined by Student’s t-test for autoxidation and heme release, and via the lack of overlap of
95% confidence intervals of means for non linear curve fitting of ferryl reduction rates).
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ascorbate can reduce reactive damaging oxidative Hb species,
such as ferryl heme. Accessibility of heme to plasma reduc-
tants, such as ascorbate, is therefore desirable to maintain in
an HBOC and we tested whether the PEGylation of A12 pre-
vented access of ascorbate to the heme. In wild type Hb, this
reaction is fastest in the α subunit. PEGylation on the
α-subunit in A12 did not prevent access of ascorbate to the
ferryl heme, although there was a decrease in the rate of
reduction (decreased Vmax, increased Km). However, there were
equivocal effects at the β-subunit (increased Vmax, increased
Km).
Discussion
The number of approved biopharmaceuticals incorporating
PEG linkages is now well into double figures.11 In most of the
current FDA approved proteins, the PEG is introduced in a non
site-specific manner resulting in a heterogenous product.31
These products will inevitably include proteins of differing
activity and longevity, diminishing the efficacy of the resulting
product. Therefore, there is interest in developing site-specific
PEGylated products,31 as evidenced by the approvals of human
recombinant granulocyte colony-stimulating factor
Pegfilgrastim (Neulasta®) and the PEGylated antibody frag-
ment of (TNF)-α monoclonal antibody, certolizamab
(Cimzia®). In Pegfilgrastim, site-directed reductive alkylation
was used for covalent attachment of PEG to the N-terminal
amine group;32 in certolizamab, MAL-PEG is reacted with a
C-terminal cysteine in a humanized mouse Fab’ fragment. Our
approach uses similar chemistry to certolizamab but instead
engineers a target cysteine on the surface of the protein. This
is not unique and has been tried in many other proteins,
although to our knowledge it is the first time it has been used
in Hb.
Any introduced site-specific PEG-protein construct must
pass three tests: the PEGylation reaction must be efficient; it
must not significantly diminish the activity of the protein; and
it must not introduce unwanted side reactions. Of the protein
we tested A12 (Cys93Ala/αAla19Cys) best fulfills these criteria.
The efficiency of the A12 PEGylation reaction is good
(70–80% depending on conditions, Fig. 8). This compares well
with the variety of novel surface cysteine reactive residues in
granulocyte-macrophage colony-stimulating factor, where
efficiencies varies from 45–89%.33 It also compares favorably
with the 8–72% yields for the 11 mutations tested in human
thyroid stimulating hormone.34 It is also significant that
increasing the PEG : Hb ratio above 3 : 1 and increasing the
time of incubation greater than 1 hour had relatively minor
effects on this efficiency. This is important, given that grams
of PEGylated Hb would be required in any final HBOC product
and thus production costs would be a significant fraction of
the cost of any commercial product. As a comparison the
Hemospan MP4 HBOC was produced with a 20 : 1 PEG : Hb
ratio.21 The natural βCys93 site (A1) is more exposed and reac-
tive in the R state (favored in oxyHb) whereas it is more buried
in the T state (favored in deoxyHb).30 However, PEGylation
efficiency in A12 is independent of the T or R quaternary state
(Fig. 5). This gives additional flexibility in the production of
PEGylated A12, which can use either anaerobic or aerobic con-
ditions; in the latter scenario as CO does not hinder
PEGylation, it could be added to prevent any oxidation that
might occur during processing.
DTT treatment increased the PEG reactivity in some of our
preparations, suggesting the presence of disulfide bridges
between the introduced cysteine residues. SEC analysis also
revealed the presence of a fraction of covalent tetrameric state
for both A12 and A13 (Fig. 6). The covalent tetramer could be
formed between two dimers of the same Hb molecule, or from
two tetramers; these tetramers would then subsequently dis-
sociate into a hybrid tetramer. This has been shown previously
with Hb Polytaur (α-Cys104Ser/ α-Ser9Cys human HbA –
β-Cys93Ala bovine Hb), although in that case, the formation of
a disulfide bridge between two tetramers resulted in the for-
mation of a cyclic trimer of linked tetramers in a time-depen-
dent oxidation process.35 However, disulfide bridges cannot
completely explain the small amount of DTT resistant Hb
dimer formation that is seen in denaturing SDS-PAGE gels
(Fig. 4). It is likely these are due, at least in part, to metal-cata-
lyzed oxidative deamination at the β-subunit36 occurring
during the recombinant expression. Consistent with this band
excision followed by digestion and peptide mass fingerprinting
revealed the presence of predominantly β-subunit. It is clear
therefore that, although the A12 mutation appears an ideal
candidate for site-specific PEGylation of Hb, more work will be
needed to improve the purification process.
Although Hb has a range of activities,37–39 we focused on its
primary role in oxygen transport and metabolism. The most
exhaustive studies on the effects of site directed mutations on
the oxygen affinity of myoglobin (Mb) and Hb have been
undertaken by Olson and co-workers.40 They studied over
300 mutants and demonstrated two classes of mutations with
significant effects: those that cause local structural changes in
the distal heme pocket that change the rate of oxygen entry/
exit to/from the heme or alter of the stability of the iron–oxy
bond; and those outside the heme pocket near the α1β1 and
α2β2 interface that cause global structural perturbations by dis-
rupting the equilibrium between the R (high affinity) and T
(low affinity) quaternary states of Hb.41 These active site and
allosteric mutations acting independently and in combination
have been used to design Hb molecules with P50 values that
range from 0.2 to 200 μM, using both allosteric and active site
mutations.42 The cysteines we introduced were chosen to be
outside the heme pocket and distant from the α1β1 and α2β2
interface, enabling PEGylation that had no effect on both
oxygen affinity and cooperative oxygen binding.
To our knowledge the PEGylations on A12 (αAla19Cys) and
A13 (βAla13Cys) are the only ones shown to have no significant
effect on both oxygen affinity and co-operativity. There is no
consensus for the ideal optimum oxygen affinity of an extra-
cellular HBOC. A higher affinity might better deliver oxygen to
severely hypoxic tissues, whereas a lower, more physiological,
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affinity might be better for bulk oxygen transport. These
differing strategies are exemplified43 by the higher oxygen
affinity (5 Torr) for Sangart’s MP4 product, versus values
similar to native human Hb for Northfield’s Polyheme product
(26 Torr) or the lower than native affinities in Biopure’s (now
HbO2 Therapeutics) Hemopure® product (40 Torr). In this
paper we measured oxygen affinities under “pseudophysiologi-
cal” conditions, similar to those existing outside the red blood
cell where high concentrations of physiological effectors such
as BPG are not present. So the affinities we measured are lower
than those cited above. However, the key fact is that
PEGylation of the A12/A13 mutations had no effect on oxygen
affinity. These mutations can therefore be used as a template
to design other desirable properties without the final
PEGylation step modifying oxygen affinity.
As well as mutations specifically designed to modify oxygen
affinity,42 other desirable properties that could be added to the
A12 template could include adding mutations in the heme
pocket to decrease NO scavenging,44 increase ferryl/ferric
reduction45,46 or increase nitrite reductase activity.45 Of poten-
tial concern is that in order to engineer homogenous
PEGylation at a single site we modified the native reactive
cysteine residue, β93. The nitrosation of this site has been con-
sidered essential for red cell hypoxic signaling,47 though the
extent of this effect is controversial.48,49 Our view is that the
removal of this reactive residue in extracellular Hb, by repla-
cing it with alanine, is desirable given its tendency to oxidize
and cause damage in other HBOCs.50 It is also true that any
HBOC infused will still be a minority of the total blood Hb
compared to that remaining in the red cell (and which will
obviously have intact, reactive βCys93). Therefore, in terms of
nitric oxide metabolism we feel the priority in the design of an
extracellular HBOC is to decrease the Hb nitric oxide dioxygen-
ase activity and/or increase the nitrite reductase activity.
However, we note that, if desired,19 it might be possible to par-
tially protect βCys93 reactivity when PEGylating at α19Cys or
β13Cys, depending on the reaction conditions chosen. Clearly
this would not be an option if βCys93 itself was chosen as the
PEGylation site.
Given its ease of PEGylation and the lack of effect on favor-
able oxygen binding, we chose to explore further the reactivity
of A12 (Cys93Ala/αAla19Cys) in terms of its stability and oxi-
dative reactivity, focusing on heme loss and the autoxidation
of ferrous(oxy) Hb to ferric(met)Hb. Heme loss was studied
from the ferric Hb as this rate is far greater than the loss from
the ferrous redox state51 and is likely to be the physiologically
relevant rate for an HBOC in vivo.51,52 The effect of mutations
on the rate of globin autoxidation is less well characterized
than effects on oxygen affinity.40,42 Although some globins
with high oxygen affinity have very low autoxidation rates,53 no
Hb mutations that would be able to mirror these effects have
been engineered. In general Hb and Mb modifications have no
effect or cause an increase in oxidation rate54 and heme
loss.42,55 The βCys93Ala/αAla19Cys double mutation itself had
no effect on the rate of autoxidation or heme loss, but interest-
ingly, and promisingly, PEGylation at α19Cys decreased both
autoxidation and heme loss. This contrasts with PEGylation at
βCys93 which elicits the opposite effects.17
It is not easy a priori to predict which surface sites are most
efficient for PEGylation in any protein;31 there is always some
trial and error involved. However, we conclude that it is indeed
possible to engineer an efficient site-specific mutation for
PEGylation in human Hb that has no effect on oxygen binding
properties and an improvement in the potentially damaging
properties of autoxidation and heme loss. PEGylation of Hb at
the βCys93Ala/αAla19Cys may therefore prove a useful template
as a component of a novel HBOC especially if additional
mutations, such as those that decrease nitric oxide scavenging
or oxidative stress, are added.
Material and methods
Hb protein purification
Native Hb was purified from human blood as described pre-
viously.56 Recombinant DNA fragments encoding the Hb
mutations were purchased from Epoch Life Science (Missouri
City, Texas, USA). E. coli BL21 (DE3) cells were transformed
with pETDuet-1 plasmid containing wild type or mutant genes
grown in 2 L Erlenmeyer flasks containing 1.4 L of Luria–
Bertani growth medium at 37 °C. The cells were agitated at 180
rpm until an OD600 ∼ 2 was achieved, following which Hb
expression was induced by 0.5 mM IPTG (isopropyl β-D-1-thio-
galactopyranoside). Also added for enhanced heme synthesis
was 0.25 mM ALA (aminolevulinic acid) and 0.1 mM ferric
citrate. Cultures were bubbled with pure CO gas. The flasks
were sealed thoroughly with rubber bungs and grown for a
further 18 h at 30 °C and 90 rpm. Cells were then harvested by
centrifugation at 4000 rpm for 20 minutes at 4 °C. Cell pellets
were resuspended in 10 mM sodium phosphate buffer, pH 6.0,
before being lysed using an Avestin C3 Emulsiflex homogen-
iser. The samples were kept in the ferrous CO bound form
(carbonmonoxyHb, HbCO) throughout the purification
process to prevent oxidation. Purification of the Hb protein by
cation exchange, anion exchange and affinity chromatography
was performed as described previously.57 Samples were stored
in liquid nitrogen as the HbCO form and converted to ferrous
(oxy) or ferric(met) depending on the reaction measured as
described previously.57
Protein PEGylation
For specific PEGylation of reactive thiol mutants, PEGylation
buffer (100 mM HEPES, 100 mM NaCl, 1.2 mM sodium phos-
phate, 1 mM EDTA, pH 7) was bubbled with carbon monoxide
or nitrogen before adding protein samples. For each sample,
absorption spectra were collected in the range of 450–700 nm
to check concentration and oxidation state of the proteins:
firstly, each sample was diluted with CO-equilibrated buffer
(5 µL of stock protein samples + 115 µL of CO-equilibrated
buffer) to check the fraction of oxidized Hb. Then, sodium
dithionite was added to the sample to reduce oxidized hemo-
globin, thus obtaining pure HbCO. Another spectrum was
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then acquired to determine protein concentration by using a
molar extinction coefficient of HbCO of 191 mM−1 cm−1.58 All
the samples were brought to 1 mM concentration (on
monomer basis) with the CO or nitrogen equilibrated
PEGylation buffer for PEGylation in the CO or deoxy forms,
respectively. The final volume of the samples to be PEGylated
was 200 µL. 20 kDa MAL-PEG (MeO-PEG-mal, Iris Biotech) was
added to the protein solutions in 12 : 1 ratio PEG : Hb tetramer.
The samples were left to react at 25 °C for 60 min. MAL-PEG
stock solution (10 mM) was prepared from powder just before
the reaction. The reaction was quenched by the addition of
2 µL of a 0.9 M Cys solution to each sample. Unreacted
reagents and unmodified Hb were removed by ultrafiltration/
diafiltration (UF/DF) with 100 kDa MWCO centrifuge filters. A
colored flow through was observed for all the samples due to
unmodified and/or monoPEGylated Hb. After UF/DF, absorp-
tion spectra were collected on the samples to check concen-
tration and oxidation state. The samples were then frozen and
stored at −80 °C. PEGylation under anaerobic conditions was
carried out in vials fluxed with inert gas, at 25 °C, by adding
deoxygenated solutions of reagents using the same protein/
reagents ratio used for the CO-saturated samples. Before
PEGylation, when hemoglobins were deoxygenated, sodium
ascorbate (0.2 mM) was also added as a reducing agent during
the reaction.
Cysteine reactivity
Sodium p-hydroxy mercury benzoate (PMB) was freshly pre-
pared prior to each experiment as follows: PMB was dissolved
in a small volume of 1 M NaOH. Next, a drop of acetic acid was
added. Finally, the PMB solution was cleared by addition of 1
M NaOH drop-wise until the cloudiness was completely gone.
Hb solutions were diluted to 20 μM in 70 mM sodium phos-
phate (pH 7.2) buffer into 1 mL quartz cuvettes and CO was
bubbled through the sample. Absorption spectra were
recorded after each addition of PMB. Alternative reagents in
place of PMB may be used in the measurement of protein sulf-
hydryls, these include Ellman’s reagent and 4,4′-
dithiodipyridine.59
Oxygen binding measurements
P50 measurements were carried out by diluting the stock Hb
solutions in 100 mM HEPES, 100 mM NaCl, 1.2 mM sodium
phosphate, 1 mM EDTA, pH 7.0. The final protein concen-
tration was 100 μM (heme basis). Oxygen equilibrium curves
were measured at 25 °C, as previously reported.60 For each
sample, the absorption spectrum (equilibrated in air) was col-
lected immediately after thawing. Sodium ascorbate and cata-
lase were added to the solution before titrations to reduce
metHb and to limit its formation during titration. The
samples were deoxygenated using a helium flow and then
equilibrated with different oxygen partial pressures. A titration
required about 5 hours.
SDS-PAGE
The purity of Hb and degree of PEGylation was assessed by
1D-PAGE. SDS-PAGE analyses (Fig. 4 and 8) were performed
using NuPAGE 4–12% bis–tris gels and NuPAGE MES SDS
running buffer (Invitrogen). Prior to analysis SDS-PAGE
samples were prepared by mixing the Hb and PEG–Hb with
NuPAGE LDS sample buffer (×4) in a 3 : 1 ratio. Each analysis
was carried out with 1 µg sample loading per well.
Electrophoresis was carried out for 35 min at 200 V. Gels were
stained using InstantBlue™ (Expedeon) and imaged using an
ImageQuant™ LAS4010 system (GE Healthcare). Bands were
quantified by densitometry and were sized relative to Novex
Sharp Pre-stained Protein Standards (Invitrogen). SDS-PAGE
analyses (Fig. 5) were performed using denaturating protein
electrophoresis (SDS-PAGE in 12% acrylamide/bisacrylamide),
loading 10 µg of unmodified and PEGylated samples. Protein
samples were added with sample buffer and brought to 100 °C
for 10 minutes. Protein staining was carried out with Biosafe®
Coomassie. The SDS-PAGE gels were scanned using a
ChemiDoc® imager (Biorad) and bands intensity was evalu-
ated by densitometric analysis.
LC-MS (Q-TOF)
LC-MS analyses were conducted on a Waters NanoAcquity
system using an POROSHELL 300SBC3 column (2.1 ×
12.5 mm, 5 µm). The mobile phase was composed of aqueous
phase (buffer A) and organic phase (buffer B). Mobile phase A
was LC-MS grade water containing 0.1% (v/v) formic acid and
mobile phase B was LC-MS grade acetonitrile containing 0.1%
(v/v) formic acid. The temperature of the column oven was
maintained at 60 °C. MS analysis was conducted on a Waters
XEVO-G2S Q-TOF mass spectrometer system using electrospray
ionisation in positive ion mode (ESI+).
Size exclusion chromatography
Size exclusion chromatography (SEC) was carried out using a
TOSOH TSKgel Super SW 3000 column (4.6 mm × 30 cm) and
guard column (4.6 mm × 3.5 cm). Hb and PEG–Hb sample
were isocratically eluted with 200 mM sodium phosphate, pH
6.8 (200 mM KCl, 15% 2-propanol). For each analysis 10 μg of
sample was injected and elution was performed over 20 min at
25 °C with UV detection at 280 nm.
MALDI TOF mass spectrometry
MALDI TOF mass spectra were acquired in the m/z range
10–40 kDa using a 4800 MALDI TOF/TOF (SCIEX) instrument.
Protein samples were mixed with 10 mg mL−1 α-cyano-4-hydro-
xycinnamic acid (HCCA) matrix solubilized in 75% (v/v) aceto-
nitrile–2.5% (v/v) trifluoracetic acid in 1 : 9 ratio (v/v) and 1 µL
was spotted onto a MALDI TOF plate. Spectra were obtained
mediating 500 laser shots in linear positive ion mode.
Autoxidation kinetics (oxyHb to metHb)
The spontaneous autoxidation of 10 µM oxyHb in 70 mM
sodium phosphate buffer, pH 7.2, at 37 °C, was monitored
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optically. Time courses (406–500 nm) of oxy to met conversion
were fit to single exponential functions minimizing the least
squares using Microsoft Excel™ Solver61 or using the non-
linear curve fitting function in Kaleidagraph™ (Version 4.2).
Data are the mean of six experiments.
Heme release kinetics
The heme binding scavenger sperm whale (SW) myoglobin
(Mb) (H64Y/V67F) was expressed, purified and the heme
removed as described previously.62 Sucrose was added to
prevent protein precipitation and the reaction followed at
lower than physiological pH to increase the rate of heme
release and facilitate discrimination between proteins.63 3 µM
metHb was incubated with 30 µM apo SW Mb (H64Y/V67F) in
0.15 M sodium acetate, 0.4 M sucrose, pH 5 at 37 °C and reac-
tions monitored using a Tecan Infinite M200 Pro plate reader.
The time courses (600–650 nm) for removal of Hb from metHb
to apo Mb were fit to a single exponential function minimizing
the least squares using Microsoft Excel™ Solver61 or using the
nonlinear curve fitting function in Kaleidagraph™ (Version
4.2). Data are the mean of three experiments.
Ferryl Hb reduction by ascorbate
Ferryl Hb was made by adding a 3 : 1 ratio of H2O2 : metHb
and waiting 10–15 minutes until the spectral change was com-
plete (confirmed by the optical spectra). Trace catalase (1–5
nM) was then added to remove unreacted H2O2. Ferryl
reduction (ferryl to met) was then monitored following the
addition of varying concentrations of sodium ascorbate
(0–1000 μM) to 5 μM ferryl Hb in 70 mM sodium phosphate
buffer, pH 7.2. Double exponential fits of the time courses
(425–406 nm), assigning the faster phase to the α-subunit and
the slower phase to the β-subunit63 were used to calculate the
pseudo first order rate constant for ferryl reduction at each
[ascorbate]. The autoreduction rate constant at zero [ascorbate]
was then subtracted from each rate and the corrected data fit
to a rectangular hyperbola using nonlinear regression to deter-
mine the Vmax and KM (errors are SEM from the curve fits, n =
12 data points). The program Kaleidagraph™ (Version 4.2) was
used for this analysis.
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